1. Home
  2. IMUX vs ASRT Comparison

IMUX vs ASRT Comparison

Compare IMUX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.62

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$0.75

Market Cap

75.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMUX
ASRT
Founded
2016
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.8M
75.1M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
IMUX
ASRT
Price
$0.62
$0.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$6.00
$3.00
AVG Volume (30 Days)
1.2M
418.0K
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$137,354,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9.22
52 Week Low
$0.56
$0.51
52 Week High
$1.39
$1.01

Technical Indicators

Market Signals
Indicator
IMUX
ASRT
Relative Strength Index (RSI) 34.77 44.17
Support Level $0.66 $0.75
Resistance Level $0.70 $0.80
Average True Range (ATR) 0.04 0.04
MACD -0.00 0.00
Stochastic Oscillator 5.75 63.68

Price Performance

Historical Comparison
IMUX
ASRT

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: